Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (≥12 to <18 Years)

NCT04864561 is registered in ClinicalTrials.gov with Valneva Austria GmbH as lead sponsor.

NCT NCT04864561
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04864561 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Observer-Blind, Controlled, Superiority Study To Compare The Immunogenicity Against COVID-19, Of VLA2001 Vaccine To AZD1222 Vaccine, In Adults Including a Randomized, Observer-blind, Placebo Controlled Part in Adolescents (≥12 to <18 Years)
Lead sponsor
Valneva Austria GmbH
Phase
Phase 3
Overall status
Completed
Start date
April 26, 2021
Completion date
March 13, 2023
Enrollment
4,034 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2 virus infection